〔Abstract〕 Objective To analyze the clinical efficacy of sodium valproate combined with oxcarbazepine in the treatment of children with epilepsy. MethodsA total of 56 children with epilepsy admitted to Xiamen Children's Hospital from March 2021 to March 2022 were selected and divided into a control group (sodium valproate treatment) and an observation group (sodium valproate combined with oxcarbazepine treatment) according to the random number table method, with 28 cases in each group. The clinical efficacy, seizure condition, neurological function and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 92.86 %, higher than 71.43 % of the control group, and the difference was statistically significant (P < 0.05). After treatment, the duration and frequency of seizures in the observation group were less than those in the control group, and the differences were statistically significant (P < 0.05). After treatment, the level of brain-derived neurotrophic factor (BDNF) of the observation group was higher than that of the control group, and the levels of central nervous system specific protein (S-100β), high mobility group protein 1 (HMGB-1) and insulin-like growth factor 1 (IGF-1) were lower than those of the control group, and the differences were statistically significant (P < 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Sodium valproate combined with oxcarbazepine can improve the clinical efficacy of children with epilepsy, reduce the frequency of seizures, shorten the duration of seizures, and reduce neurological damage.